Morton Grove to market Amantadine Hydrochloride Syrup

Drug Store News, Feb 15, 1999

The Food and Drug Administration has granted Morton Grove Pharmaceuticals approval to market Amantadine Hydrochloride Syrup, USP 50 mg/5 mL, for the prophylaxis and treatment of infection caused by strains of influenza A virus. Amantadine Hydrochloride is also indicated for the treatment of Parkinsonism and drug-induced extrapyramidal reactions.

According to the FDA approval letter, the product was found to be therapeutically bioequivalent to Symmetrel Syrup, 50 mg/5 mL, marketed by DuPont Merck Pharmaceutical Co.